This is topic Lessons Learned.. in forum Micro Penny Stocks, Penny Stocks $0.10 & Under at Allstocks.com's Bulletin Board.


To visit this topic, use this URL:
http://www.allstocks.com/stockmessageboard/ubb/ultimatebb.php/ubb/get_topic/f/8/t/030893.html

Posted by jackbequick on :
 
***PKTX.. Lessons Learned through Research over the years and getting ready for the jump to next level in Phase One Testing with Protokinetix's Molecule..AAGP.
This is an old PR News release from 2007.. Just to show that PKTX's molecule has gained a lot of interest from the scientific community in this present day..
.ProtoKinetix Highlights AAGP(TM) Development and Production Strategy
Business Wire News Releases....Protokinetix, has moved from this point in time(2007)forward....Greatly!

ProtoKinetix Inc. (PKTX) summarizes the highlights of the scientific accomplishments attained over the last 24 months to develop a commercially viable group of products.

..The first hurdle was to determine that the AAGPTM molecule was stable and lacked toxicity. Upon these confirmations, PKTX concentrated on human cell preservation at various temperatures. Early studies showed a greater than 300% increase in cell preservation down to -20 oC.

..Efficacy test results showed a 98% red blood cell preservation after being subjected to -15 oC for 9 hrs as opposed to 100% mortality for cells not treated. Further tests showed a significant reduction of platelet aggregation from 22 oC to 0 oC. Scientists at the University of Rouen expanded the family of AAGPTM molecules and found them to be stable and safe.

..A third party laboratory found that AAGPTM increased heart cell and heart tissue survivability. AAGP™ was shown to slow the aging process of human skin cells at temperatures ranging from 37o C (core body temperature) down to 0o C.

..More intense stress to human skin cells using H2O2 and UV-C resulted in successful preservation when treated with AAGPTM. World wide patents and subsequent extensions were then filed.
After laying the above scientific foundations, in 2006 ProtoKinetix began to concentrate on trials that were targeted toward specific markets.

..At the request of a cosmetic corporation, the Company conducted trials using very low concentrations of AAGPTM. The results showed minimal decline in the preservative effects attained. Again, targeting the cosmetic market, PKTX showed that AAGPTM proves to be a powerful additive compared to coenzyme Q10 and side by side.

..Third party testing showed that lengthy exposure to AAGPTM maintained cell integrity and function even with high concentrations of the molecule (15 mg/ml).
Patent expansions included AAGPTM molecules ranging from the very smallest (320 daltons) single amino acid based molecule through to the largest (2.2 kilodaltons) AAGPTM molecule that would have any practical application.

..INSA (Francès National Institute of Applied Science) chose AAGPTM as its project to present at the annual GECO Conference. ProtoKinetix’ lead scientist was awarded the prestigious Francinov Award for the development of the AAGPTM family of molecules.
Recent studies have shown that AAGPTM significantly reduces inflammation.

..This new development has opened up several avenues for research and business development. The latest UV exposure experiments suggest that AAGPTM not only protects cells from UV light but may also be acting at a molecular level to induce the repair of damaged cells.

..A new market for AAGPTM has been opened up by the discovery that the addition of this molecule to a solution of DMSO in cryopreservation of cell lines increased the thawed out cell viability by 100%.

..Capitalizing on the significant scientific breakthroughs accomplished over the last few months, ProtoKinetix has a wide range of choices for maximizing the commercial value of the Company. PKTX’ focus for 2007 is to launch AAGPTM into the markets which require no regulatory approval to a fast track approval.

***These markets include:
1. Skin care applications – anti-aging and anti-oxidant additives for cosmetic use
2. Sun protection agents – protection and repair
3. Cryopreservation of cells and tissues
4. Preservation of organs, islets and skin cells for transplantation

..In anticipation of successful contractual negotiations in the first quarter of this year, ProtoKinetix has entered into discussion with major chemical corporations to dramatically ramp up the production of the AAGPTM family of molecules. As of this date, PKTX has entered into 6 specific application development agreements with major universities, institutions and corporations.

..These developments will very quickly establish the market value of AAGPTM which will ultimately determine the long term value of the Company.
 


© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2